Literature DB >> 19221516

Towards development of stable formulations of a live attenuated bacterial vaccine: a preformulation study facilitated by a biophysical approach.

Yuhong Zeng1, Haihong Fan, Gary Chiueh, Binh Pham, Russ Martin, David Lechuga-Ballesteros, Vu L Truong, Sangeeta B Joshi, C Russell Middaugh.   

Abstract

Development of optimal formulation conditions stabilizing live attenuated bacterial vaccines is impeded by traditional methods used for viability measurement. To facilitate preformulation studies of such vaccines, spectroscopic techniques capable of providing real-time and high throughput information have been employed to obtain a global stability profile for a live attenuated Ty21a bacterial typhoid vaccine over a wide range of pH (4 to 8) and temperature (10 to 85 degrees C). Using the data obtained from fluorescence and circular dichroism techniques, an empirical phase diagram (EPD) has been subsequently constructed, which suggests that Ty21a cells exist in at least four apparent physical phases related to different viability states, with the most stable phase at pH 6 and 7 at temperatures below 30 degrees C. A slightly basic pH (pH 8) appears to decrease the fluidity of the cell membrane, whereas acidic pH conditions are detrimental to membrane integrity over the entire temperature range. Based on the above stability profile, a fluorescence-based high throughput screening assay has been developed to test the stabilizing effects of various compounds at different concentrations. Amongst other promising stabilizers, 10% sucrose and 0.15 M glutamic acid display the greatest protective effects, with an increase of about 10 degrees C in the transition temperature of Ty21a cells. Preliminary studies have also been performed on foam dried formulations as an alternative approach to further stabilize Ty21a cells. The data show that 10% sucrose and trehalose both increase the in-process and storage stabilities of the cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221516     DOI: 10.4161/hv.5.5.7559

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  7 in total

1.  Formulation and stabilization of Francisella tularensis live vaccine strain.

Authors:  Satoshi Ohtake; Russell A Martin; Atul Saxena; David Lechuga-Ballesteros; Araceli E Santiago; Eileen M Barry; Vu Truong-Le
Journal:  J Pharm Sci       Date:  2011-04-13       Impact factor: 3.534

Review 2.  A rational, systematic approach for the development of vaccine formulations.

Authors:  Garry L Morefield
Journal:  AAPS J       Date:  2011-02-23       Impact factor: 4.009

Review 3.  Multidimensional methods for the formulation of biopharmaceuticals and vaccines.

Authors:  Nathaniel R Maddux; Sangeeta B Joshi; David B Volkin; John P Ralston; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2011-06-06       Impact factor: 3.534

4.  Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines.

Authors:  Satoshi Ohtake; Russell Martin; Atul Saxena; Binh Pham; Gary Chiueh; Manuel Osorio; Dennis Kopecko; Deqi Xu; David Lechuga-Ballesteros; Vu Truong-Le
Journal:  Vaccine       Date:  2011-02-05       Impact factor: 3.641

5.  A stable live bacterial vaccine.

Authors:  Nitesh K Kunda; Denis Wafula; Meilinn Tram; Terry H Wu; Pavan Muttil
Journal:  Eur J Pharm Biopharm       Date:  2016-03-25       Impact factor: 5.571

6.  Biophysical characterization of the type III secretion tip proteins and the tip proteins attached to bacterium-like particles.

Authors:  Shyamal P Choudhari; Xiaotong Chen; Jae Hyun Kim; Maarten L Van Roosmalen; Jamie C Greenwood; Sangeeta B Joshi; William D Picking; Kees Leenhouts; C Russell Middaugh; Wendy L Picking
Journal:  J Pharm Sci       Date:  2014-06-10       Impact factor: 3.534

7.  Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis.

Authors:  B Kim Lee Sim; Minglin Li; Manuel Osorio; Yun Wu; Tint T Wai; Johnny W Peterson; Eric R James; Sumana Chakravarty; Lixin Gao; Rui Xu; Natasha Kc; Richard E Stafford; William S Lawrence; Linsey A Yeager; Jennifer E Peel; Satheesh K Sivasubramani; Ashok K Chopra; Svetlana Filippova; Stephen L Hoffman
Journal:  NPJ Vaccines       Date:  2017-06-15       Impact factor: 7.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.